Atherosclerotic Cardiovascular Disease in Rheumatoid Arthritis: Impact of Inflammation and Antirheumatic Treatment
Patients with rheumatoid arthritis (RA) are at approximately 1.5-fold risk of atherosclerotic cardiovascular disease (CVD) compared with the general population, a phenomenon resulting from combined effects of traditional CVD risk factors and systemic inflammation. Rheumatoid synovitis and unstable a...
Saved in:
| Main Authors: | Anne Mirjam Kerola, Silvia Rollefstad, Anne Grete Semb |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Radcliffe Medical Media
2021-05-01
|
| Series: | European Cardiology Review |
| Online Access: | https://www.ecrjournal.com/articleindex/ecr.2020.44 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Antirheumatic treatment is associated with reduced serum Syndecan-1 in Rheumatoid Arthritis.
by: Gia Deyab, et al.
Published: (2021-01-01) -
Biological use influences the impact of inflammation on risk of major adverse cardiovascular events in rheumatoid arthritis
by: George Athanasios Karpouzas, et al.
Published: (2024-09-01) -
Relative Importance of Disease-Modifying Antirheumatic Drug Attributes for Patients with Rheumatoid Arthritis
by: Poudel N, et al.
Published: (2025-08-01) -
Is it possible to discontinue glucocorticoids in rheumatoid arthritis with the use of synthetic disease-modifying antirheumatic drugs?
by: O. B. Iaremenko, et al.
Published: (2023-07-01) -
Rationales for discontinuation of disease-modifying antirheumatic drugs, biologic agents, and tofacitinib in rheumatoid arthritis
by: Yu. V. Muraviev, et al.
Published: (2018-12-01)